Recent progress in vaccines for amebiasis.
The persistence of amebiasis as a global health problem, despite the availability of effective treatment, has led to the search for vaccines to prevent this deadly disease. Recent clinical studies suggest that mucosal immunity could provide some protection against recurrent intestinal infection with E. histolytica, but there is contradictory evidence about protective immunity after amebic liver abscess. Progress in vaccine development has been facilitated by new animal models that allow better testing of potential vaccine candidates and by the application of recombinant technology to vaccine design. Oral vaccines utilizing amebic antigens either co-administered with some form of cholera toxin or expressed in attenuated strains of Salmonella or Vibrio cholera have been developed and tested in animals for mucosal immunogenicity. Although there has been significant progress on a number of fronts, there are unanswered questions regarding the effectiveness of immune responses in preventing disease in man and, as yet, no testing of any of these vaccines in humans has been performed.
Snow
Margaret J
MJ
Department of Medicine and Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Stanley
Samuel L
SL
D004749:Entamoebiasis / Q000517:prevention & control*; D005240:Feasibility Studies; D006801:Humans; D016052:Protozoan Vaccines / Q000627:therapeutic use*
D016052:Protozoan Vaccines